We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biotech Start-Up Nexomics Biosciences Gets Off the Ground
News

Biotech Start-Up Nexomics Biosciences Gets Off the Ground

Biotech Start-Up Nexomics Biosciences Gets Off the Ground
News

Biotech Start-Up Nexomics Biosciences Gets Off the Ground

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biotech Start-Up Nexomics Biosciences Gets Off the Ground"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nexomics Biosciences Inc., a recently-formed, New Jersey-based biotechnology company, applies platform technologies based on large scale protein production, Nuclear Magnetic Resonance (NMR), and X-ray crystallography for use in drug discovery efforts.

The company provides customers with services in bioinformatics, protein production and structural biology for lead discovery, optimization and development programs. In addition, Nexomics Biosciences will also pursue in-house drug discovery projects on proprietary targets to identify novel small molecule therapeutics.

Nexomics Biosciences has signed a comprehensive license agreement with Rutgers, the State University of New Jersey, that provides Nexomics rights to a portfolio of intellectual property, including a suite of bioinformatics software and an early stage antibiotic screening methodology.

In addition, the agreement gives Nexomics rights to use and further develop a novel ribosomal RNA methyltransferase assay for identifying specific binding and inhibition of R1mA proteins from bacterial species. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.

An additional agreement has been announced with the Center for Advanced Biotechnology and Medicine (CABM), a research and teaching center that provides Nexomics access to laboratory space and equipment. Under the service agreement, Nexomics Biosciences will have access to a number of scientific facilities supporting molecular biology, fermentation, protein purification, and Nuclear Magnetic Resonance (NMR).
Advertisement